Skip to content
Back to meeting Original
Oncology Nursing News· @OncNursingNews · X·· 4 hours agoScore70

KRASCENDO

Body

Divarasib extended median overall survival to 17.7 months vs 12.0 months with sotorasib or adagrasib in the Krascendo 1 trial, with new olomorasib and daraxonrasib data close behind: https://hubs.li/Q04Cj2Jg0 #OncologyNursing #OncNurse #ESMO26 #LungCancer #PancreaticCancer

8 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

Source: Oncology Nursing News · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.